Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 484-488

  De Lange, S M ^a   van Groeningen, C J ^a   Kroep, J R ^a   Van Bochove, A ^b   Snijders, J F ^a   Peters, G J ^a   Pinedo, H M ^a   Giaccone, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ZAANS MEDICAL CENTER   (Netherlands)

Author keywords

Advanced gastric cancer; Cisplatin; Gemcitabine

Indexed keywords

CISPLATIN; COLONY STIMULATING FACTOR; CREATININE; DEXAMETHASONE; ERYTHROPOIETIN; GEMCITABINE; MAGNESIUM SULFATE; ONDANSETRON; POTASSIUM CHLORIDE; SODIUM CHLORIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEARING LOSS; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SIDE EFFECT; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1842503066     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh109     Document Type: Article

References (31)

1. Maehara Y, Baba H, Sugimachi K. Adjuvant chemotherapy for gastric cancer: A comprehensive review. Gastric Cancer 2001; 4: 175-184.
2. Fuchs CS. Chemotherapy for advanced gastric cancer: Where do we stand? [Editorial] J Clin Oncol 1997: 15: 3299-3300.
3. Neijt JP, ten Bokkel Huinink WW, van der Burg ME et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-1372.
4. Al-Sarraf M. Head and neck cancer: Chemotherapy concepts. Semin Oncol 1988; 15: 70-85.
5. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000; 18: 122-130.
6. Muggia F. Cisplatin update. Semin Oncol 1991; 18 (Suppl 3): 1-4.
7. Fichtinger-Schepman AMJ, Veer van der JL, Hartog den JHJ. Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification and quantification. Biochemistry 1985; 24: 707-713.
8. van Moorsel CJA, Peters GJ, Pinedo HM. Gemcitabine: Future prospects of single-agent and combination studies. Oncologist 1997; 2: 127-134.
9. Christman K, Kelsen D, Saltz L, Tarassoff PG. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994; 73: 5-7.
10. Sessa C, Aamdal S, Wolff I et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 471-472.
11. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β -D-arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-4031.
12. Huang P, Chubb S, Hertel LW et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991: 51: 6110-6117.
13. Peters GJ, van der Wilt CL, van Moorsel CJ et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87: 227-253.
14. Bergman AM, Ruiz van Haperen VWT, Veerman G et al. Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 1996; 2: 521-530.
15. van Moorsel CJA, Pinedo HM, Veerman G et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br J Cancer 1999; 80: 981-990.
16. Yang LY, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000; 6: 773-781.
17. van Moorsel CJA, Kroep JR, Pinedo HM et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumours. Ann Oncol 1999; 10: 441-448.
18. Kroep JR, Peters GJ, van Moorsel CJA et al. Gemcitabine-cisplatin: A schedule finding study. Ann Oncol 1999; 10: 1503-1510.
19. National Cancer Institute. Guidelines for reporting adverse reactions. Bethesda, MD: National Cancer Institute 1998.
20. WHO Handbook for Reporting Results of Cancer Treatment, Offset Publication No. 48. Geneva, Switzerland: World Health Organization 1979.
21. Gehan EA. The determination of the number of patients required in a preliminary and a follow up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-353.
22. Castellano D, Lianes P, Paz-Arez L. A phase II study of novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small cell lung cancer. Ann Oncol 1998; 9: 457-459.
23. Cardenal F, Lopez-Carbrerizo MP, Anton A et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999; 17: 12-18.
24. Lacave AJ, Baron FJ, Anton LM et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A phase II trial. Ann Oncol 1991; 2: 751-754.
25. Rougier P, Ducreux M, Mahjoubi M et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas: A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30: 1263-1269.
26. Mochizuki F, Fujii M, Kasakura Y et al. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer. J Cancer Res Clin Oncol 2002; 128: 493-496.
27. Roth A, Kolaric K, Zupanc D et al. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: A randomized study. Tumori 1999; 85: 234-238.
28. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
29. Mitachi Y, Sakata Y, Ohtsu A et al. Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: A multicenter phase I/II study. Gastric Cancer 2002; 5: 160-167.
30. 2/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 2001; 92: 500-559.
31. Benson AB, Catalano PJ, Meropol NJ et al. Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 2003; 22: 243 (Abstr 975).